This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bet on These 3 Low-Beta Stocks to Combat Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Amphastar Pharmaceuticals (AMPH), AMN Healthcare (AMN) & Sensus Healthcare (SRTS) are well poised to gain.
Fresenius Medical's (FMS) New Dialyzer to Boost Patient Outcome
by Zacks Equity Research
Fresenius Medical's (FMS) latest dialyzer is expected to better serve dialysis patients because of its design.
Is AMN Healthcare (AMN) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
AMN Healthcare (AMN) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why You Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.
Smith+Nephew (SNN) Introduces Real Intelligence & CORI System
by Zacks Equity Research
Smith+Nephew (SNN) debuts new brand of enabling technology solutions as well as its next-generation handheld robotics platform in Canada.
Here's Why You Should Hold on to Integra (IART) Stock for Now
by Zacks Equity Research
Investors are optimistic about Integra (IART) given its better-than-expected results and robust performance of the CSS arm in the third quarter.
Allscripts' (MDRX) Services Leveraged by Next Level Urgent Care
by Zacks Equity Research
Allscripts' (MDRX) Touchworks platform and Microsoft Azure hosting & services will be implemented across all Next Level Urgent Care's sites in Houston.
Here's Why You Should Hold on to Syneos Health (SYNH) for Now
by Zacks Equity Research
Investors about optimistic about Syneos Health (SYNH) given its better-than-expected results as well as strong segmental performance during the third quarter.
Here's Why You Should Add Omnicell (OMCL) To Your Portfolio
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its better-than-expected results in the third quarter and robust segmental performance.
Walgreens (WBA) to Offer COVID-19 Vaccine Booster Shots
by Zacks Equity Research
Individuals aged 18 years or older are eligible to avail Pfizer, Moderna or Johnson & Johnson COVID-19 vaccine boosters from Walgreens' (WBA) stores.
Surging Earnings Estimates Signal Upside for AMN Healthcare (AMN) Stock
by Zacks Equity Research
AMN Healthcare (AMN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks.com featured highlights include: Vista Outdoor, AMN, Standard Motor, and Albertsons Companies
by Zacks Equity Research
Zacks.com featured highlights include: Vista Outdoor, AMN, Standard Motor, and Albertsons Companies
Zacks.com featured highlights include: AutoNation, AMN, Olin, Franchise, and Harley-Davidson
by Zacks Equity Research
Zacks.com featured highlights include: AutoNation, AMN, Olin, Franchise, and Harley-Davidson
5 Finest PEG Stocks for GARP Investors
by Urmimala Biswas
Stocks that have qualified the screening are AutoNation (AN), AMN Healthcare Services (AMN), Olin Corporation (OLN), Franchise Group (FRG) and Harley-Davidson (HOG).
Combat Market Volatility With These 4 Low-Beta Stocks
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Vista Outdoor (VSTO), AMN Healthcare (AMN), Standard Motor (SMP) & Albertsons (ACI) are well poised to gain.
AMN vs. GDRX: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
New Strong Buy Stocks for November 9th
by Zacks Equity Research
AMN, BVH, MRBK, SGH, and TX have been added to the Zacks Rank #1 (Strong Buy) List on November 9th.
AMN Healthcare (AMN) Loses 13.1% Despite Q3 Earnings Beat
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.
Progyny (PGNY) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Progyny (PGNY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AMN Healthcare Services (AMN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AMN Healthcare (AMN) delivered earnings and revenue surprises of 29.10% and 12.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
AMN Healthcare Services (AMN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AMN Healthcare (AMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
AMN or GDRX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. GDRX: Which Stock Is the Better Value Option?
Walgreens (WBA) to Make Additional Investment in VillageMD
by Zacks Equity Research
Walgreens (WBA) announced a $5.2-billion investment in VillageMD to bolster its strategic position in delivering value-based primary care.
Boston Scientific (BSX) Reports Data Backing Eluvia Stent
by Zacks Equity Research
The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.